Select Page


Sound Choice Pharmaceutical Institute (SCPI), a pro-life public educational organization encouraging safe and moral medicines and therapeutics, has given backing to a new biotech firm which will be providing vaccines to the public which have not been tainted by abortion.
SCPI has announced their first successful support for a new biotech firm – AVM Biotechnology. AVM has a new vaccines division that will be importing safe and effective vaccines for those who, for philosophical or moral reasoning, are opposed to the vaccines that are tainted with human DNA contaminants.

AVM Biotechnology has added the vaccine division in addition to their regenerative medicine and human therapeutics division in response to the request from numerous parents and grandparents who have chosen not to vaccinate until moral and ethical vaccines are available.
Debi Vinnedge, Executive Director of Children of God for Life – a pro-life organization which has focused on the vaccine issue – said of the effort to produce ethic vaccines: "Sound Choice Pharmaceutical Institute is a light at the end of a very long, dark tunnel for thousands of parents who want to protect their children and communities – but are concerned about the moral implications for that choice. If we have an ethical alternative – and with the support of SCPI and AVM Biotechnology we hope to have that in the coming months – we can comply with vaccination recommendations from the American Pediatric Association and still comply with our faith."

According to Centers for Disease Control (CDC) data, as many as 10% of United States children are not fully immunized. The reasons vary, but most focus on the safety and efficacy of the vaccines that are available. It is estimated that about 3% of the population will not vaccinate based on the knowledge that the vaccines are produced using human cells from an aborted fetus.

Although a moral objection to vaccinations is an accepted objection in some states, others may only accept a medical or philosophical objection. Each state delineates their own specific acceptable objection criteria and process.
"AVM's original business plan was to focus on adult stem cell regenerative medicine due to the safety and economics. It wasn't until we were approached by COG for Life that we rethought our original strategy and realized – we could do both." says Dr. Theresa Deisher, president of SCPI.

Dr. Deisher, a Stanford doctoral graduate in molecular and cellular physiology and former Principal Scientist with Amgen says she is excited about being able to help a community of parents and children that have, up to this point, been discriminated against. "I can see an opportunity to help not only these parents, but also safeguard the children and the communities in which they live and ultimately our nation's health," stated Dr. Deisher. "This is a small niche market – one that the larger pharmaceutical industry is not likely to venture into – but one that we will gladly support."
See the websites for more info:
[WASHINGTON, November 11, 2008]